Top Page
Chimeric Therapeutics Ltd.
(Sydney:CHM)
Chimeric Therapeutics Ltd. (CHM) vs. iShares MSCI Australia ETF (EWA)
Chimeric Therapeutics Ltd. Business Overview & Revenue Model
Chimeric Therapeutics Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.12M | 3.97M | 7.46M | 0.00 | 2.62M | 2.65K |
| Gross Profit | 8.70M | 3.12M | 7.45M | 3.54M | 1.67M | -844.31K |
| EBITDA | -7.37M | -9.08M | -11.30M | -28.59M | -13.62M | -14.26M |
| Net Income | -6.64M | -10.43M | -12.53M | -25.92M | -15.90M | -15.11M |
Balance Sheet | ||||||
| Total Assets | 21.57M | 21.57M | 15.27M | 22.38M | 34.88M | 36.50M |
| Cash, Cash Equivalents and Short-Term Investments | 5.76M | 5.76M | 3.05M | 5.37M | 18.38M | 22.41M |
| Total Debt | 0.00 | 0.00 | 3.59M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 19.60M | 19.60M | 12.80M | 16.71M | 9.17M | 11.37M |
| Stockholders Equity | 1.97M | 1.97M | 2.47M | 5.66M | 25.71M | 25.13M |
Cash Flow | ||||||
| Free Cash Flow | -4.96M | -7.28M | 10.11K | -16.43M | -13.69M | -14.15M |
| Operating Cash Flow | -4.96M | -7.28M | -7.54M | -16.32M | -13.15M | -8.84M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -112.19K | -577.86K | -5.30M |
| Financing Cash Flow | 10.05M | 10.05M | 8.26M | 253.38K | 9.50M | 36.54M |
Chimeric Therapeutics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$186.52M | -6.66 | ― | ― | ― | 0.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$79.92M | -8.35 | -49.72% | ― | ― | 10.78% | |
48 Neutral | AU$9.02M | -19.05 | -8.72% | ― | ― | 71.10% | |
45 Neutral | AU$11.05M | ― | -469.35% | ― | ― | 46.28% | |
44 Neutral | AU$105.70M | -13.24 | -47.98% | ― | 700.00% | 26.88% | |
42 Neutral | AU$23.38M | -4.61 | -157.93% | ― | ― | -36.89% |
Chimeric Therapeutics Ltd. Corporate Events
Chimeric Therapeutics has issued 309,900,722 new ordinary shares on 7 January 2026, expanding its share capital without providing a prospectus-style disclosure under the Corporations Act provisions governing fundraising. The company affirmed it is up to date with its financial reporting and continuous disclosure obligations and stated that there is no excluded information requiring disclosure, signalling regulatory compliance around the capital issuance for existing and prospective investors.
The most recent analyst rating on (AU:CHM) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
Chimeric Therapeutics Limited has applied to the ASX for quotation of 309,900,722 ordinary fully paid shares, to be issued and quoted from 7 January 2026 under its existing ticker CHM. The large issuance, tied to previously announced transactions, will significantly expand the company’s quoted share base, potentially affecting liquidity and ownership structure for investors as the new securities commence trading.
The most recent analyst rating on (AU:CHM) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
Chimeric Therapeutics has disclosed that Paul Hopper has ceased to be a substantial shareholder in the company as of 31 December 2025, following the filing of a statutory notice. The change in substantial holding status arises solely from dilution of Hopper’s percentage interest due to a recent share placement, with the company emphasising that there has been no on-market or off-market sale of shares by him, indicating that his absolute shareholding remains unchanged while the company’s expanded capital base has altered ownership proportions.
The most recent analyst rating on (AU:CHM) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
Chimeric Therapeutics has issued 466,666,665 new ordinary shares on 31 December 2025, expanding its share capital without providing a prospectus or other disclosure document, in reliance on the provisions of section 708A of the Corporations Act. The company affirmed that it is up to date with its financial reporting and continuous disclosure obligations and stated there is no excluded information requiring disclosure, signalling that the large capital issuance is being conducted within existing regulatory frameworks and without undisclosed market-sensitive information for investors.
The most recent analyst rating on (AU:CHM) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
Chimeric Therapeutics Limited has applied for quotation on the ASX of 466,666,665 new fully paid ordinary shares, to be issued on 31 December 2025 under its existing capital management program. The substantial increase in quoted securities signals a significant capital move that may affect the company’s ownership structure and liquidity, with implications for existing shareholders as the enlarged share base begins trading on the market.
The most recent analyst rating on (AU:CHM) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
Chimeric Therapeutics Limited has announced a proposed capital raising via a placement and related securities issue, seeking to issue up to 690,099,278 new fully paid ordinary shares, 4,000,000 convertible notes, and a substantial number of options expiring in 2029 and 2030. The transaction, slated for completion around 11 March 2026, would significantly expand the company’s capital base and provide additional funding flexibility, potentially diluting existing shareholders but strengthening its financial position to support ongoing operations and future growth initiatives.
Chimeric Therapeutics Limited has notified the market of the issue of 16,667,000 unquoted options under an employee incentive scheme, with various exercise prices and expiry dates, effective 12 December 2025. The additional unquoted equity securities expand the company’s pool of staff incentives, aligning employee remuneration with shareholder interests and potentially impacting future capital structure depending on option exercise and subsequent share issuance.
Chimeric Therapeutics has disclosed a change in director Miles Prince’s interests, confirming the issue of 16,667,000 unlisted options to him following shareholder approval at the company’s 25 November 2025 Annual General Meeting. The grant, made for nil cash consideration and without any disposal of existing securities, increases Prince’s direct exposure to the company’s equity and further aligns his incentives with shareholders, signalling continued confidence in Chimeric’s strategic direction in the competitive oncology biotech space.
Chimeric Therapeutics has requested and been granted a trading halt on its securities by the ASX as it prepares to announce details of a material capital raising. The halt will remain in place until the anticipated announcement is released or until the start of normal trading on 23 December 2025, signalling that the company is undertaking a significant funding initiative that could influence its capital structure and near-term strategic activities.
Chimeric Therapeutics announced that its novel CAR-T cell therapy, CHM 1107, has been granted Orphan Drug Designation by the FDA for the treatment of gastric cancer. This designation provides the company with incentives such as tax credits and potential market exclusivity, enhancing its position in the cell therapy industry and addressing significant unmet medical needs in gastric cancer treatment.
Chimeric Therapeutics announced significant board changes following shareholder feedback from its recent AGM, including the appointment of a new Chairperson and a Non-Executive Director nominated by a major shareholder. The company is optimistic about its future as it progresses its CHM CDH17 Phase 1/2 trial, which is showing promising results in tumor shrinkage and disease control, with more data expected soon.
Chimeric Therapeutics Ltd. announced the resignation of Paul Hopper from his position as a director, effective November 25, 2025. This change in the board may impact the company’s strategic direction and investor confidence, given Hopper’s significant holdings of 21,232,142 ordinary shares and 31,580,882 options. The transition could influence the company’s operations and its positioning in the competitive biotechnology market.
Chimeric Therapeutics Ltd. announced the results of its Annual General Meeting, where all resolutions were conducted via poll. A significant outcome was the ‘first strike’ against the Remuneration Report under the Corporations Act, indicating shareholder dissatisfaction with executive pay. Additionally, Paul Hopper retired as Executive Chairman, with Phillip Hains appointed as Acting Chair until a new Chair is announced. The meeting also saw the election of Professor Henry Miles Prince as a Director and approval for issuing incentive options to him, while similar options for Paul Hopper were not approved. These developments may impact the company’s governance and strategic direction.
Chimeric Therapeutics Ltd. has issued a news release containing forward-looking statements, highlighting potential risks and uncertainties related to their clinical trials and regulatory approvals. The announcement underscores the company’s commitment to advancing its cell therapy solutions while acknowledging the challenges and costs associated with clinical trials and regulatory processes.
Chimeric Therapeutics has received a $4.5 million R&D tax incentive from the Australian Government, recognizing its research and development activities in 2025. This financial boost supports Chimeric’s ongoing efforts in advancing its cell therapy programs, potentially enhancing its position in the oncology treatment market and benefiting stakeholders through continued innovation in cancer therapies.
Chimeric Therapeutics announced promising results from its CHM CDH17 Phase 1/2 clinical trial, showing 75% disease control among evaluable subjects at 28 days. The trial, which focuses on advanced colorectal cancer, gastric cancer, and gastrointestinal NETs, demonstrated stable disease in all patients treated at Dose Level 2, with one patient maintaining stable disease for nearly a year without additional therapy. This progress underscores the potential impact of CHM CDH17 as a novel CAR-T cell therapy targeting CDH17, a biomarker linked to poor prognosis in gastrointestinal tumors.
Chimeric Therapeutics has temporarily suspended its CHM CORE-NK + Vactosertib Phase 1b clinical trial due to supply chain issues unrelated to the treatment itself. The trial aims to treat patients with advanced colorectal and blood cancers, and the company expects to resolve the issue soon, potentially impacting its operations and stakeholder confidence.
Chimeric Therapeutics Limited responded to an ASX query regarding the ADVENT-AML clinical trial results. The company disclosed that no dose-limiting toxicities were observed, and CORE-NK cells persisted in patients’ blood. Notably, 57% of high-risk frontline subjects showed clinical responses, with two new complete responses in AML. This information, although not initially disclosed, is considered to have a potential material impact on the company’s securities when combined with additional new data.
Chimeric Therapeutics has reported significant progress in its CHM CDH17 Phase 1/2 clinical trial, advancing to dose level 2 with promising safety and efficacy results. The trial has shown manageable safety profiles and encouraging disease control in patients, with notable tumor size reductions in colorectal and neuroendocrine cancers. Additionally, the company has strengthened its leadership by appointing Professor Miles Prince as a Non-Executive Director and has signed a local manufacturing agreement with the New South Wales Government, potentially enhancing its operational capabilities.